“Developing enhanced methods to objectively evaluate cognitive function is a critical component of the next generation digital medicine – a component that is required to not only advance the basic research in neurodegenerative disease but also one that is required for the development of improved clinical interventions. Altoida’s novel approach to developing digital biomarkers of cognitive function will promote the elaboration of specific ‘biotypes’ of neurodegenerative disease. Understanding neurodegenerative biotypes will dramatically improve our ability to conduct a differential diagnosis at the primary care level. Improved diagnostics will provide healthcare professionals with the key information necessary to precisely adapt clinical interventions to personalize the patient’s cognitive care. This will ultimately lead to improved outcomes of care and to reduced healthcare costs.” Dr. Walter Greenleaf Ph.D., a neuroscientist and Distinguished Visiting Scholar working at the Stanford University Virtual Human Interaction Lab